Cantor Fitzgerald Issues Negative Forecast for SLNO Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Soleno Therapeutics in a note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($3.44) for the year, down from their previous forecast of ($2.85). Cantor Fitzgerald has a “Overweight” rating and a $123.00 price target on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

SLNO has been the topic of several other reports. Lifesci Capital raised Soleno Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 4th. Robert W. Baird lifted their price objective on shares of Soleno Therapeutics from $102.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Soleno Therapeutics in a research note on Tuesday, April 15th. Guggenheim raised their price target on shares of Soleno Therapeutics from $81.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Finally, Laidlaw boosted their price objective on Soleno Therapeutics from $75.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, March 27th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Soleno Therapeutics currently has an average rating of “Buy” and an average target price of $106.78.

Soleno Therapeutics Trading Down 2.9%

Shares of NASDAQ SLNO opened at $74.44 on Monday. Soleno Therapeutics has a 12-month low of $36.93 and a 12-month high of $80.99. The company has a market cap of $3.75 billion, a price-to-earnings ratio of -22.42 and a beta of -2.67. The stock’s 50 day simple moving average is $64.48 and its 200 day simple moving average is $54.66.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, May 7th. The company reported ($0.95) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.19.

Insider Buying and Selling

In other news, Director Matthew Pauls sold 5,937 shares of Soleno Therapeutics stock in a transaction that occurred on Friday, March 28th. The shares were sold at an average price of $71.55, for a total value of $424,792.35. Following the transaction, the director now owns 6,500 shares of the company’s stock, valued at $465,075. The trade was a 47.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Patricia C. Hirano sold 3,782 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $70.11, for a total transaction of $265,156.02. Following the completion of the sale, the insider now owns 27,036 shares in the company, valued at $1,895,493.96. The trade was a 12.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 942,672 shares of company stock valued at $64,058,781 over the last three months. Company insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Legal & General Group Plc boosted its position in shares of Soleno Therapeutics by 9.2% in the 4th quarter. Legal & General Group Plc now owns 23,471 shares of the company’s stock valued at $1,055,000 after purchasing an additional 1,983 shares during the period. Barclays PLC lifted its stake in Soleno Therapeutics by 149.3% during the third quarter. Barclays PLC now owns 52,545 shares of the company’s stock valued at $2,652,000 after buying an additional 31,467 shares in the last quarter. Emerald Advisers LLC boosted its holdings in shares of Soleno Therapeutics by 85.4% in the fourth quarter. Emerald Advisers LLC now owns 580,919 shares of the company’s stock worth $26,112,000 after buying an additional 267,585 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Soleno Therapeutics by 13.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 217,550 shares of the company’s stock worth $9,779,000 after acquiring an additional 24,953 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Soleno Therapeutics by 47.0% during the fourth quarter. Sei Investments Co. now owns 16,444 shares of the company’s stock valued at $739,000 after acquiring an additional 5,258 shares during the period. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.